MA43313B1 - Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation - Google Patents

Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation

Info

Publication number
MA43313B1
MA43313B1 MA43313A MA43313A MA43313B1 MA 43313 B1 MA43313 B1 MA 43313B1 MA 43313 A MA43313 A MA 43313A MA 43313 A MA43313 A MA 43313A MA 43313 B1 MA43313 B1 MA 43313B1
Authority
MA
Morocco
Prior art keywords
methods
opioid receptor
making
same
delta opioid
Prior art date
Application number
MA43313A
Other languages
English (en)
Other versions
MA43313A (fr
Inventor
Aimee Crombie Speerschneider
Dennis Shinji Yamashita
Philip Michael Pitis
Michael John Hawkins
Guodong Liu
Daubert Tamara Ann Miskowski
Catherine C K Yuan
Kargbo Robert Borbo
Robert Jason Herr
Donna Romero
Gregory J Pacofsky
Original Assignee
Trevena Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevena Inc filed Critical Trevena Inc
Publication of MA43313A publication Critical patent/MA43313A/fr
Publication of MA43313B1 publication Critical patent/MA43313B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des modes de réalisation de la présente invention concernent, notamment, des composés ou leurs sels pharmaceutiquement acceptables ou leurs compositions pharmaceutiques pour moduler l'activité du récepteur opioïde delta, biaisé ou non biaisé, et/ou des méthodes de traitement de la douleur, des migraines, des maux de tête, de la dépression, de la maladie de parkinson, de l'anxiété, et/ou de la vessie hyperactive, et d'autres troubles et états décrits dans la description, ou d'une quelconque de leurs combinaisons.
MA43313A 2015-09-02 2016-08-30 Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation MA43313B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562213203P 2015-09-02 2015-09-02
PCT/US2016/049526 WO2017040545A1 (fr) 2015-09-02 2016-08-30 Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation

Publications (2)

Publication Number Publication Date
MA43313A MA43313A (fr) 2018-10-03
MA43313B1 true MA43313B1 (fr) 2022-06-30

Family

ID=58188367

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43313A MA43313B1 (fr) 2015-09-02 2016-08-30 Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation

Country Status (21)

Country Link
US (3) US10246436B2 (fr)
EP (2) EP4086249A3 (fr)
JP (2) JP6898310B2 (fr)
KR (1) KR20180041751A (fr)
CN (2) CN108025002B (fr)
AU (2) AU2016315720B2 (fr)
CA (1) CA3015702A1 (fr)
DK (1) DK3344248T3 (fr)
ES (1) ES2920130T3 (fr)
HK (2) HK1254498A1 (fr)
HR (1) HRP20220735T1 (fr)
HU (1) HUE058819T2 (fr)
IL (1) IL257503B (fr)
LT (1) LT3344248T (fr)
MA (1) MA43313B1 (fr)
MD (1) MD3344248T2 (fr)
PL (1) PL3344248T3 (fr)
PT (1) PT3344248T (fr)
RS (1) RS63319B1 (fr)
SI (1) SI3344248T1 (fr)
WO (1) WO2017040545A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110446495B (zh) * 2017-02-17 2023-09-05 特维娜有限公司 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
KR20190129867A (ko) * 2017-02-17 2019-11-20 트레베나, 인코포레이티드. 5-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법
CN111533682B (zh) * 2020-05-29 2022-03-01 清华大学 帕罗西汀及其类似物的制备方法
CN113880815B (zh) * 2020-07-03 2024-03-29 中国药科大学 一类吲哚衍生物及其制备方法和用途
WO2022093904A1 (fr) * 2020-10-27 2022-05-05 Trevena, Inc. Formes cristallines et amorphes d'un modulateur delta-opioïde
WO2023070605A1 (fr) * 2021-10-29 2023-05-04 Trevena, Inc. Procédés de préparation de composés modulateurs du récepteur delta-opioïde contenant un aza-hétérocycle à 6 chaînons

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE352811B (fr) 1971-06-04 1973-01-15 Pharmacia Ab
US3960150A (en) 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US3867519A (en) 1972-04-27 1975-02-18 Alza Corp Bioerodible drug delivery device
SE375007B (fr) 1972-11-30 1975-04-07 Pharmacia Ab
US3963025A (en) 1974-09-16 1976-06-15 Alza Corporation Ocular drug delivery device
JPS5825980B2 (ja) 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
US4186184A (en) 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4303637A (en) 1980-04-04 1981-12-01 Alza Corporation Medication indicated for ocular hypertension
DK231088D0 (da) * 1988-04-28 1988-04-28 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
US5086063A (en) 1988-03-28 1992-02-04 Du Pont Merck Pharmaceutical Company 4-aryl-4-piperidine (or pyrrolidine or hexahydroazepine) carbinols and heterocyclic analogs thereof
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
TR199801929T2 (xx) * 1996-03-29 1998-12-21 Pfizer Inc. Benzil(iden)-laktam t�revleri, bunlar�n 5-HT1A resept�rlerinin (ant)agonistler olarak kullan�mlar� .
CA2257950A1 (fr) 1996-06-28 1998-01-08 Merck & Co., Inc. Promedicaments antagonistes de recepteurs de fibrinogenes
WO1999045925A1 (fr) * 1998-03-10 1999-09-16 Research Triangle Institute Nouveaux composes opiaces et leurs procedes de preparation et d'utilisation
WO2001032178A1 (fr) 1999-10-29 2001-05-10 Novo Nordisk A/S Utilisation de piperidines 3,4-substituees
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
CN100372850C (zh) * 2003-02-12 2008-03-05 神经研究公司 新的8-氮杂-双环[3.2.1]辛烷衍生物和它们作为单胺神经递质再摄取抑制剂的用途
SE0301445D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
EP1670476A4 (fr) 2003-09-30 2009-05-27 Merck & Co Inc Antagonistes du recepteur de la tachykinine a base de phenyle pyrrolidine ether
WO2006019768A1 (fr) 2004-07-16 2006-02-23 Schering Corporation Dérivés d' hydantoine pour le traitement de troubles inflammatoires
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
US7098203B2 (en) 2004-07-20 2006-08-29 Bristol-Myers Squibb Company Homopiperidine derivatives as NK-1 antagonists
US7872023B2 (en) 2005-02-17 2011-01-18 Research Triangle Institute Kappa opioid receptor ligands
TW200804307A (en) 2005-10-27 2008-01-16 Synta Pharmaceuticals Corp Process for preparing mesylate salts of IL-12 inhibitory compounds
CN101316816B (zh) 2005-12-01 2011-07-27 弗·哈夫曼-拉罗切有限公司 5-羟色胺转运体(sert)抑制剂
US20070142389A1 (en) 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
EP2001844A2 (fr) 2006-03-14 2008-12-17 Amgen, Inc Derives bicycliques de l'acide carboxylique utiles dans le traitement de troubles metaboliques
WO2008068471A1 (fr) 2006-12-04 2008-06-12 Orexo Ab Nouvelle composition pharmaceutique non susceptible d'abus comprenant des opioïdes
TWI443090B (zh) * 2007-05-25 2014-07-01 Abbvie Deutschland 作為代謝性麩胺酸受體２（ｍｇｌｕ２ 受體）之正向調節劑之雜環化合物
CA2695211A1 (fr) 2007-08-07 2009-02-12 F. Hoffmann-La Roche Ag Composes de pyrrolidine aryle-ether utilises comme antagonistes des recepteurs nk3
NZ586082A (en) * 2007-11-16 2013-03-28 Neuraxon Inc Indole compounds and methods for treating visceral pain
US8664214B2 (en) 2010-03-30 2014-03-04 AbbVie Deutschland GmbH & Co. KG Small molecule potentiators of metabotropic glutamate receptors I
US8507535B2 (en) 2010-07-07 2013-08-13 Hoffmann-La Roche Inc. Methyl-pyrrolidine ether derivatives
WO2012112933A1 (fr) * 2011-02-18 2012-08-23 The Scripps Research Institute Différenciation dirigée de cellules précurseurs d'oligodendrocytes vers un destin cellulaire myélinisant
WO2012129562A2 (fr) 2011-03-24 2012-09-27 The Scripps Research Institute Composés et procédés pour l'induction de la chondrogenèse
BR112014010271A2 (pt) 2011-10-31 2017-04-18 Xenon Pharmaceuticals Inc compostos de benzenossulfonamida e seu uso como agentes terapêuticos
RU2616610C2 (ru) 2012-01-31 2017-04-18 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производное пароксетина
WO2013182612A1 (fr) 2012-06-07 2013-12-12 Bayer Pharma Aktiengesellschaft Inhibiteurs de transport du glucose
CA2896202A1 (fr) * 2012-12-28 2014-07-03 Purdue Pharma L.P. Morphinanes substitues et utilisation de ceux-ci
EP3183232B1 (fr) 2014-08-22 2023-05-03 The Arizona Board of Regents on behalf of The University of Arizona Dérivés de 1-aryléthyl-4-acylaminopipéridine substitués à titre de modulateurs des récepteurs d'opioïdes/adrénorécepteurs alpha et leur procédé de préparation
US10329283B2 (en) 2015-06-26 2019-06-25 The Regents Of The University Of Michigan G protein-coupled receptor kinase inhibitors and methods for use of the same

Also Published As

Publication number Publication date
HRP20220735T1 (hr) 2022-09-02
EP3344248A1 (fr) 2018-07-11
MA43313A (fr) 2018-10-03
HK1254498A1 (zh) 2019-07-19
CN108025002A (zh) 2018-05-11
CN108025002B (zh) 2022-05-13
CA3015702A1 (fr) 2017-03-09
LT3344248T (lt) 2022-06-27
EP4086249A2 (fr) 2022-11-09
RS63319B1 (sr) 2022-07-29
EP4086249A3 (fr) 2023-02-15
EP3344248B1 (fr) 2022-03-23
AU2016315720A1 (en) 2018-03-15
ES2920130T3 (es) 2022-08-01
SI3344248T1 (sl) 2022-07-29
WO2017040545A1 (fr) 2017-03-09
US20200231564A9 (en) 2020-07-23
JP2018527354A (ja) 2018-09-20
PL3344248T3 (pl) 2022-07-18
HUE058819T2 (hu) 2022-09-28
US20230203002A1 (en) 2023-06-29
EP3344248A4 (fr) 2019-07-10
US10246436B2 (en) 2019-04-02
US11465980B2 (en) 2022-10-11
US20190202803A1 (en) 2019-07-04
JP6898310B2 (ja) 2021-07-07
JP7463318B2 (ja) 2024-04-08
CN114773318A (zh) 2022-07-22
IL257503A (en) 2018-04-30
US20170210725A1 (en) 2017-07-27
AU2016315720B2 (en) 2021-02-25
DK3344248T3 (da) 2022-06-20
KR20180041751A (ko) 2018-04-24
MD3344248T2 (ro) 2022-10-31
HK1257927A1 (zh) 2019-11-01
PT3344248T (pt) 2022-06-29
AU2021203337A1 (en) 2021-06-24
JP2021138744A (ja) 2021-09-16
IL257503B (en) 2021-10-31

Similar Documents

Publication Publication Date Title
MA43313B1 (fr) Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d&#39;utilisation
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA38380A1 (fr) Inhibiteurs quinazoline de l&#39;activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA35348B1 (fr) 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu&#39;inhibiteurs de btk
MA42410B1 (fr) Oxystérols et leurs méthodes d&#39;utilisation
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
MA33593B1 (fr) Composés hétérocycliques et leurs utilisations
EA201391670A1 (ru) 1,3-оксазины в качестве ингибиторов bace1 и/или bace2
MA44948A1 (fr) Inhibiteurs de bace 1
MY158494A (en) Pharmaceutically active compounds as axl inhibitors
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA38260A1 (fr) Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d&#39;agoniste adrénergique beta2 et une activité d&#39;antagoniste muscarinique m3
MA38810A1 (fr) Inhibiteurs de rorc2 méthodes d&#39;utilisation associées
ATE522526T1 (de) 4-(3-(2-(phenyl)morpholino)-2-oxopyrrolidin-1-y )-n-(thiazol-2-yl)benzolsulfonamidderivate und verwandte verbindungen als ionenkanalmodulatoren zur behandlung von schmerzen
MX2014003408A (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1).
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
MA37763B1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu&#39;inhibiteurs de bace1
MA46229A (fr) Composés d&#39;hétéroaryle carboxamide en tant qu&#39;inhibiteurs de ripk2
MA38697A1 (fr) 4-(5-(4-chlorophényl)-2-(2-cyclopropylacétyl)-1,4-diméthyl-1h-pyrrol-3-yl)benzène-sulfonamide à titre de modulateur du nachr alpha 7
MA38009B1 (fr) Composes d&#39;azaindoline substitues qui ont une activite inhibitrice de la proteine d&#39;apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu&#39;antagonistes des récepteurs des orexines
MX2023010542A (es) Uso de mevidaleno y otros moduladores alostéricos positivos d1 para ralentizar la progresión de la enfermedad de parkinson.
MA39153A1 (fr) Nouveaux composés hétérocycliques
MA38280B1 (fr) Composes 1,2,3,4-tetrahydroisoquinoleine substitues inhibiteurs de la proteine arginine-methyltransferase 5
MA37741B1 (fr) Dérivés de benzimidazole-proline